Shares of Cytori Therapeutics took a big bit hit today after the company disclosed in a press release that it had suspended enrollment in its ATHENA and ATHENA II trials. This kind of news is never a good sign, but the principal investigator of the trial tells me that he believes the current problems are surmountable and that the trials are still viable.
…
Click here to read the full post on Forbes.
Speak Your Mind